NDATOPICALSYSTEM
Approved
Sep 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
3/8 — Basic
BONDLIDO (lidocaine) by PharmaIN is amide-type local anesthetic and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONDLIDO is a topical lidocaine transdermal system approved by the FDA in September 2025 for localized pain relief. It is an amide-type local anesthetic that works by stabilizing neuronal membranes and inhibiting ionic fluxes required for nerve impulse initiation and conduction. The product targets patients seeking non-systemic pain management via transdermal delivery.
LOE Approaching2.3 years to LOE
Competitive pressure of 25% indicates moderate market challenge; early-stage product with limited commercial infrastructure and small team requirements.
Mechanism of Action
amide-type local anesthetic and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses.
Pharmacologic Class:
Amide Local Anesthetic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Started Jun 2026
100 enrolled
Chin Augmentation
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
Started Dec 2025
100 enrolled
CystectomyMyomectomy
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
Started Jul 2025
171 enrolled
Skin Quality Improvement
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
Started May 2025
252 enrolled
Mid Face Volume Deficit
Worked on BONDLIDO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.